We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Renalytix AI PLC Sponsored ADR (RNLX) Surges 10.4%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Renalytix AI PLC Sponsored ADR (RNLX - Free Report) shares soared 10.4% in the last trading session to close at $15.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 9.4% loss over the past four weeks.
The stock scored a strong price increase driven by the optimism surrounding the company’s latest publication of favorable study results for KidneyIntelX in The American Journal of Nephrology. The study results show that risk assessment and monitoring with KidneyIntelX can support primary care physicians and deliver proactive therapeutic management in early-stage diabetic kidney disease. The market is also upbeat about the Renalytix’s recent collaboration with Singing River Health System intended to deploy KidneyIntelX informed care management to enhance kidney health in individuals with type 2 diabetes and early-stage chronic kidney disease.
This company is expected to post quarterly loss of $0.18 per share in its upcoming report, which represents a year-over-year change of -50%. Revenues are expected to be $1.55 million, up 287.5% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Renalytix AI PLC Sponsored ADR, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RNLX going forward to see if this recent jump can turn into more strength down the road.
Image: Bigstock
Renalytix AI PLC Sponsored ADR (RNLX) Surges 10.4%: Is This an Indication of Further Gains?
Renalytix AI PLC Sponsored ADR (RNLX - Free Report) shares soared 10.4% in the last trading session to close at $15.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 9.4% loss over the past four weeks.
The stock scored a strong price increase driven by the optimism surrounding the company’s latest publication of favorable study results for KidneyIntelX in The American Journal of Nephrology. The study results show that risk assessment and monitoring with KidneyIntelX can support primary care physicians and deliver proactive therapeutic management in early-stage diabetic kidney disease. The market is also upbeat about the Renalytix’s recent collaboration with Singing River Health System intended to deploy KidneyIntelX informed care management to enhance kidney health in individuals with type 2 diabetes and early-stage chronic kidney disease.
This company is expected to post quarterly loss of $0.18 per share in its upcoming report, which represents a year-over-year change of -50%. Revenues are expected to be $1.55 million, up 287.5% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Renalytix AI PLC Sponsored ADR, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RNLX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>